Alameda, CA, October 19, 2006 -- Advanced Cell Technology, Inc.'s (OTCBB:ACTC) Michael West, Ph.D., Chairman, President and Chief Scientific Officer will be presenting at the 2006 BIO Investor Forum at the Palace Hotel, in San Francisco, California on October 19, 2006. The presentation is scheduled for 2:20 PM in the Sea Cliff room. Presentation slides and a live web cast may be accessed through the company's website at "http://www.advancedcell.com":http://www.advancedcell.com.
Dr. West will discuss ACT's recently-published data on blastomere biopsy (a novel technique that allows human ES cell lines to be produced from a single embryonic cell), thereby demonstrating the feasibility of producing new human ES cell lines without disaggregating human embryos. In addition, Dr. West will discuss recently-published positive results in preclinical studies with the company's retinal pigment epithelial (RPE) cells, and an update on ACTCellerate. As previously announced by the company, ACTCellerate is a technology platform for isolating novel purified and scalable cell types from human embryonic stem cells. New results relating to novel propagating human heart progenitor and cranial neural crest cell lines isolated using the ACTCellerate technology will be presented.
" (CLICK to Hear Live Webcast)":http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ACTC&itemid=1404420
" (CLICK to Download Presentation PDF)":/conference-presentations
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit "http://www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Investor Relations: "James Carbonara":mailto:firstname.lastname@example.org
Media Relations: "Bill Douglass":mailto:email@example.com
The Investor Relations Group
Trilogy Capital Partners